Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo

Background— Voltage-gated Na+ channels (Nav) are essential for myocyte membrane excitability and cardiac function. Nav current (INa) is a large-amplitude, short-duration spike generated by rapid channel activation followed immediately by inactivation. However, even under normal conditions, a small late component of INa (INa,L) persists because of incomplete/failed inactivation of a subpopulation of channels. Notably, INa,L is directly linked with both congenital and acquired disease states. The multifunctional Ca2+/calmodulin-dependent kinase II (CaMKII) has been identified as an important activator of INa,L in disease. Several potential CaMKII phosphorylation sites have been discovered, including Ser571 in the Nav1.5 DI-DII linker, but the molecular mechanism underlying CaMKII-dependent regulation of INa,L in vivo remains unknown. Methods and Results— To determine the in vivo role of Ser571, 2 Scn5a knock-in mouse models were generated expressing either: (1) Nav1.5 with a phosphomimetic mutation at Ser571 (S571E), or (2) Nav1.5 with the phosphorylation site ablated (S571A). Electrophysiology studies revealed that Ser571 regulates INa,L but not other channel properties previously linked to CaMKII. Ser571-mediated increases in INa,L promote abnormal repolarization and intracellular Ca2+ handling and increase susceptibility to arrhythmia at the cellular and animal level. Importantly, Ser571 is required for maladaptive remodeling and arrhythmias in response to pressure overload. Conclusions— Our data provide the first in vivo evidence for the molecular mechanism underlying CaMKII activation of the pathogenic INa,L. Relevant for improved rational design of potential therapies, our findings demonstrate that Ser571-dependent regulation of Nav1.5 specifically tunes INa,L without altering critical physiological components of the current.

[1]  Céline Marionneau,et al.  Regulation of the cardiac Na+ channel NaV1.5 by post-translational modifications. , 2015, Journal of molecular and cellular cardiology.

[2]  Brett S Phinney,et al.  CaMKII Phosphorylation of Na(V)1.5: Novel in Vitro Sites Identified by Mass Spectrometry and Reduced S516 Phosphorylation in Human Heart Failure. , 2015, Journal of proteome research.

[3]  S. Priori,et al.  Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release. , 2015, Cardiovascular research.

[4]  Sathya D. Unudurthi,et al.  Ankyrin-G Coordinates Intercalated Disc Signaling Platform to Regulate Cardiac Excitability In Vivo , 2014, Circulation research.

[5]  Michael D. Schneider,et al.  Cardiac CaM Kinase II Genes &dgr; and &ggr; Contribute to Adverse Remodeling but Redundantly Inhibit Calcineurin-Induced Myocardial Hypertrophy , 2014, Circulation.

[6]  P. Mohler,et al.  Nav channel complex heterogeneity: new targets for the treatment of arrhythmia? , 2014, Circulation.

[7]  Sathya D. Unudurthi,et al.  β(IV)-Spectrin regulates TREK-1 membrane targeting in the heart. , 2014, Cardiovascular research.

[8]  P. Milberg,et al.  Late sodium current inhibition: the most promising antiarrhythmic principle in the near future? , 2014, Current medicinal chemistry.

[9]  H. Schulman,et al.  CaMKII inhibitors: from research tools to therapeutic agents , 2014, Front. Pharmacol..

[10]  C. Antzelevitch,et al.  The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. , 2013, Cardiovascular research.

[11]  G. Hasenfuss,et al.  Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. , 2013, Journal of molecular and cellular cardiology.

[12]  C. Poggesi,et al.  Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy , 2013, Circulation.

[13]  Cheryl F. Lichti,et al.  Mass spectrometry-based identification of native cardiac Nav1.5 channel α subunit phosphorylation sites. , 2012, Journal of proteome research.

[14]  X. Wehrens,et al.  CaMKII inhibition rescues proarrhythmic phenotypes in the model of human ankyrin-B syndrome. , 2012, Heart rhythm.

[15]  L. Maier Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms! , 2012, European journal of heart failure.

[16]  Mark E. Anderson,et al.  Ca2+/Calmodulin-Dependent Protein Kinase II–Based Regulation of Voltage-Gated Na+ Channel in Cardiac Disease , 2012, Circulation.

[17]  P. Binkley,et al.  CaMKII-Based Regulation of Voltage-Gated Na+ Channel in Cardiac Disease , 2012 .

[18]  Mark E. Anderson,et al.  Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. , 2012, Circulation research.

[19]  T. Wieland,et al.  Role of RyR2 Phosphorylation at S2814 During Heart Failure Progression , 2012, Circulation research.

[20]  P. Binkley,et al.  Differential regulation of EHD3 in human and mammalian heart failure. , 2012, Journal of molecular and cellular cardiology.

[21]  D. Bers,et al.  Ca2+/Calmodulin-dependent Protein Kinase II (CaMKII) Regulates Cardiac Sodium Channel NaV1.5 Gating by Multiple Phosphorylation Sites* , 2012, The Journal of Biological Chemistry.

[22]  J. Shryock,et al.  Calmodulin kinase II and protein kinase C mediate the effect of increased intracellular calcium to augment late sodium current in rabbit ventricular myocytes. , 2012, American journal of physiology. Cell physiology.

[23]  Donald M. Bers,et al.  Requirement for Ca 2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice (Journal of Clinical Investigation (2009) 119, 5, (1230-1240) doi: 10.1172/JCI38022) , 2012 .

[24]  R. Passman,et al.  Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. , 2011, The American journal of cardiology.

[25]  Lin Wu,et al.  Late Sodium Current Contributes to the Reverse Rate-Dependent Effect of IKr Inhibition on Ventricular Repolarization , 2011, Circulation.

[26]  Mark E. Anderson,et al.  Ryanodine Receptor Phosphorylation by Calcium/Calmodulin-Dependent Protein Kinase II Promotes Life-Threatening Ventricular Arrhythmias in Mice With Heart Failure , 2010, Circulation.

[27]  Thomas J Hund,et al.  A β(IV)-spectrin/CaMKII signaling complex is essential for membrane excitability in mice. , 2010, The Journal of clinical investigation.

[28]  G. Tomaselli,et al.  Na+ channel regulation by Ca2+/calmodulin and Ca2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes. , 2010, Cardiovascular research.

[29]  Tong Zhang,et al.  Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. , 2009, The Journal of clinical investigation.

[30]  D. Roden,et al.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans , 2009, Nature Medicine.

[31]  Thomas J Hund,et al.  Regulation of the ankyrin-B-based targeting pathway following myocardial infarction. , 2009, Cardiovascular research.

[32]  Hugo A. Katus,et al.  The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload , 2009, Proceedings of the National Academy of Sciences.

[33]  Fuhua Chen,et al.  Oxidative Stress–Induced Afterdepolarizations and Calmodulin Kinase II Signaling , 2008, Circulation research.

[34]  Mark E. Anderson,et al.  Proarrhythmic Defects in Timothy Syndrome Require Calmodulin Kinase II , 2008, Circulation.

[35]  D. Murdock,et al.  The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation , 2008, Indian pacing and electrophysiology journal.

[36]  C. Antzelevitch,et al.  Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. , 2008, Heart rhythm.

[37]  G. Tenderich,et al.  Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. , 2008, Journal of molecular and cellular cardiology.

[38]  Hani N Sabbah,et al.  Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences. , 2008, American journal of physiology. Heart and circulatory physiology.

[39]  Andrew C. Zygmunt,et al.  Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation: Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine , 2007, Circulation.

[40]  Stefan Wagner,et al.  Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. , 2006, The Journal of clinical investigation.

[41]  Hani N Sabbah,et al.  Ranolazine Improves Abnormal Repolarization and Contraction in Left Ventricular Myocytes of Dogs with Heart Failure by Inhibiting Late Sodium Current , 2006, Journal of cardiovascular electrophysiology.

[42]  C. Valdivia,et al.  Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more? , 2006, British journal of pharmacology.

[43]  C. Valdivia,et al.  Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. , 2005, Journal of molecular and cellular cardiology.

[44]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[45]  J. Shryock,et al.  Antagonism by Ranolazine of the Pro-Arrhythmic Effects of Increasing Late INa in Guinea Pig Ventricular Myocytes , 2004, Journal of cardiovascular pharmacology.

[46]  J. Nerbonne Studying cardiac arrhythmias in the mouse--a reasonable model for probing mechanisms? , 2004, Trends in cardiovascular medicine.

[47]  Tong Zhang,et al.  The &dgr;C Isoform of CaMKII Is Activated in Cardiac Hypertrophy and Induces Dilated Cardiomyopathy and Heart Failure , 2003, Circulation research.

[48]  P. C. Viswanathan,et al.  Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. , 2000, Circulation research.

[49]  H. N. Sabbah,et al.  Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current , 1999, Cellular and Molecular Life Sciences CMLS.

[50]  H N Sabbah,et al.  Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. , 1998, Circulation.

[51]  C. Antzelevitch,et al.  The role of late I Na in development of cardiac arrhythmias. , 2014, Handbook of experimental pharmacology.

[52]  X. Wehrens,et al.  CaMKII inhibition rescues pro-arrhythmic phenotypes in model of human ankyrin-B syndrome , 2013 .

[53]  S. Priori,et al.  Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. , 2011, Journal of molecular and cellular cardiology.

[54]  J. Saffitz,et al.  Protein kinase Cepsilon mediates salutary effects on electrical coupling induced by ischemic preconditioning. , 2007, Heart rhythm.

[55]  R. Kass,et al.  Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. , 2005, Trends in cardiovascular medicine.

[56]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[57]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.